About Boston Biomedical
Boston Biomedical is a company based in Boston (United States) founded in 2006 was acquired by Sumitomo Dainippon Pharma in February 2012.. Boston Biomedical has raised $2 million across 2 funding rounds from investors including HHS and Sumitomo Dainippon Pharma. Boston Biomedical operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2 M (USD)
in 2 rounds
-
Latest Funding Round
$2 M (USD), Seed
Jun 15, 2010
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Sumitomo Dainippon Pharma
(Feb 29, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Boston Biomedical
Boston Biomedical has successfully raised a total of $2M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $2.0M
-
First Round
First Round
(16 Apr 2010)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2010 | Amount | Seed - Boston Biomedical | Valuation |
investors |
|
| Apr, 2010 | Amount | Grant - Boston Biomedical | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Boston Biomedical
Boston Biomedical has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Sumitomo Dainippon Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Boston Biomedical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Boston Biomedical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Boston Biomedical Comparisons
Competitors of Boston Biomedical
Boston Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Boston Biomedical
Frequently Asked Questions about Boston Biomedical
When was Boston Biomedical founded?
Boston Biomedical was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Where is Boston Biomedical located?
Boston Biomedical is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Boston Biomedical a funded company?
Boston Biomedical is a funded company, having raised a total of $2M across 2 funding rounds to date. The company's 1st funding round was a Grant of $485.53K, raised on Apr 16, 2010.
What does Boston Biomedical do?
Boston Biomedical is a privately held biotechnology company focusing on research and development of novel therapeutics to treat cancer. Beginning with initial focus on cancer stemcell pathways, company today has more than 20 clinical programs in pipeline. Two lead products at various phases of clinical trials for different types of cancer are Napabucasin and BB503. Other oncology programs include DSP-7888, an investigational agent approved by USFDA. Company got acquired by ds-pharma in 2012 for 200M USD upfront with milestone achievement being upto as high as 2.6B USD.
Who are the top competitors of Boston Biomedical?
Boston Biomedical's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Boston Biomedical's investors?
Boston Biomedical has 2 investors. Key investors include HHS, and Sumitomo Dainippon Pharma.